% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

  • qdelfan qdelfan Dec 23, 2012 12:59 PM Flag


    Starting with the JP Morgan Conference in the first week of the New Year, we'll get a read on the timetable for release of key clinical trial data in CF, RA, influenza and hep C, as well as initiation of key clinical trials for Phase 3 testing of VX 809 in CF, and Phase 2 testing in multiple autoimmune diseases using VX 509, and all oral treatment regimens in Phase 2 testing using VX 135 in hep C. Also we'll get details on the expected growth in revenue from Kalydeco approved monotherapy in G551 CF patients in Europe and the US and the timing of expected approval for the wider lable of CF patients expected to benefit from Kalydeco monotherapy in up to 15% of the CF population before year end in 2013, as well as projections on how much sales are expected from Incivek after the recent 'Black Box' warning was added to the drug's profile.. which will offset at least in part expected declining sales of Incivek. Best holiday wishes to all, and best of luck in the New Year to patient long term investors in jVertex, and especially to patients with the serious debilitating diseases whose lives will be imporved and lengthened with the success of the Vertex pipleline of medications in development.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
90.38+1.19(+1.33%)May 27 4:00 PMEDT